Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.

about

Methotrexate sensitizes drug-resistant metastatic melanoma cells to BRAF V600E inhibitors dabrafenib and encorafenib.

Item

http://www.wikidata.org/entity/Q52641587

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@en

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@nl

type

Item

label

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@en

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@nl

prefLabel

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@en

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@nl

P1476

Methotrexate sensitizes drug-r ...... rs dabrafenib and encorafenib.

@en

P2093

Christopher D Marion

http://www.w3.org/2001/XMLSchema#string

Daehwan Kim

http://www.w3.org/2001/XMLSchema#string

Kayleigh C Ross

http://www.w3.org/2001/XMLSchema#string

Kevin F Chin

http://www.w3.org/2001/XMLSchema#string

Timothy J Yen

http://www.w3.org/2001/XMLSchema#string

Vikram Bhattacharjee

http://www.w3.org/2001/XMLSchema#string

P2860

Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

A constitutively active and uninhibitable caspase-3 zymogen efficiently induces apoptosis

Resistant mechanisms to BRAF inhibitors in melanoma

Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation.

The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data

Mutations of the BRAF gene in human cancer

The Sequence Alignment/Map format and SAMtools

P304

13324-13336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.24341

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29568360

http://www.w3.org/2001/XMLSchema#string

P932

5862581

http://www.w3.org/2001/XMLSchema#string